Antigen Selection for Enhanced Affinity T-Cell Receptor-Based Cancer Therapies

Journal of Biomolecular Screening

Volumn 21, Issue 8, 2016, Pages 769-785

  Hickman, Emma S ^a   Lomax, Martine E ^a   Jakobsen, Bent K ^a  

^a Immunocore Limited   (United Kingdom)

Author keywords

mass spectrometry; oncology; review; T cell receptors; TCR

Indexed keywords

CANCER TESTIS ANTIGEN; T LYMPHOCYTE RECEPTOR; TUMOR ANTIGEN; LYMPHOCYTE ANTIGEN RECEPTOR;

CANCER CELL; CANCER IMMUNOTHERAPY; DISULFIDE BOND; HLA SYSTEM; HUMAN; MASS SPECTROMETRY; PRIORITY JOURNAL; RECEPTOR AFFINITY; REVIEW; T LYMPHOCYTE; ADAPTIVE IMMUNITY; ADOPTIVE IMMUNOTHERAPY; CYTOTOXIC T LYMPHOCYTE; GENETICS; IMMUNOLOGY; ISOLATION AND PURIFICATION; NEOPLASM;

ADAPTIVE IMMUNITY; ANTIGENS, NEOPLASM; HUMANS; IMMUNOTHERAPY, ADOPTIVE; NEOPLASMS; RECEPTORS, ANTIGEN, T-CELL; T-LYMPHOCYTES, CYTOTOXIC;

EID: 84981240512     PISSN: 10870571     EISSN: 1552454X     Source Type: Journal    
DOI: 10.1177/1087057116637837     Document Type: Review

References (179)

1. Jessy T., Immunity over Inability: The Spontaneous Regression of Cancer. J. Nat. Sci. Biol. Med. 2011, 2, 43-49.
2. Ribas A., Adaptive Immune Resistance: How Cancer Protects from Immune Attack. Cancer Discov. 2015, 5, 915-919.
3. MacKie R. M., Reid R., Junor B., Fatal Melanoma Transferred in a Donated Kidney 16 Years after Melanoma Surgery. N. Engl. J. Med. 2003, 348, 567-568.
4. Xiao D., Craig J. C., Chapman J. R., et al. Donor Cancer Transmission in Kidney Transplantation: A Systematic Review. Am. J. Transplant. 2013, 13, 2645-2652.
5. Mathisen D. J., Rosenberg S. A., The In Vivo Distribution of Transferred Syngeneic, Allogeneic, and Xenogeneic Lymphoid Cells: Implication for the Adoptive Immunotherapy of Tumors. J. Immunol. 1980, 124, 2295-2300.
6. Yron I., Wood T. A. Jr., Spiess P. J., et al. In Vitro Growth of Murine T Cells: V. The Isolation and Growth of Lymphoid Cells Infiltrating Syngeneic Solid Tumors. J. Immunol. 1980, 125, 238-245.
7. van der Bruggen P., Bastin J., Gajewski T., et al. A Peptide Encoded by Human Gene MAGE-3 and Presented by HLA-A2 Induces Cytolytic T Lymphocytes That Recognize Tumor Cells Expressing MAGE-3. Eur. J. Immuol. 1994, 24, 3038-3043.
8. van der Bruggen P., Traversari C., Chomez P., et al. A Gene Encoding an Antigen Recognized by Cytolytic T Lymphocytes on a Human Melanoma. Science 1991, 254, 1643-1647.
9. Herin M., Lemoine C., Weynants P., et al. Production of Stable Cytolytic T-Cell Clones Directed against Autologous Human Melanoma. Int. J. Cancer 1987, 39, 390-396.
10. Rosenberg S. A., Packard B. S., Aebersold P. M., et al. Use of Tumor-Infiltrating Lymphocytes and Interleukin-2 in the Immunotherapy of Patients with Metastatic Melanoma: A Preliminary Report. N. Engl. J. Med. 1988, 319, 1676-1680.
11. Van den Eynde B., Hainaut P., Herin M., et al. Presence on a Human Melanoma of Multiple Antigens Recognized by Autologous CTL. Int. J. Cancer 1989, 44, 634-640.
12. Falk K., Rotzschke O., Rammensee H. G., Cellular Peptide Composition Governed by Major Histocompatibility Complex Class I Molecules. Nature 1990, 348, 248-251.
13. Rotzschke O., Falk K., Deres K., et al. Isolation and Analysis of Naturally Processed Viral Peptides as Recognized by Cytotoxic T Cells. Nature 1990, 348, 252-254.
14. Townsend A., Ohlen C., Bastin J., et al. Association of Class I Major Histocompatibility Heavy and Light Chains Induced by Viral Peptides. Nature 1989, 340, 443-448.
15. Wallny H. J., Rammensee H. G., Identification of Classical Minor Histocompatibility Antigen as Cell-Derived Peptide. Nature 1990, 343, 275-278.
16. Bukur J., Jasinski S., Seliger B., The Role of Classical and Non-Classical HLA Class I Antigens in Human Tumors. Semin. Cancer Biol. 2012, 22, 350-358.
17. Leone P., Shin E. C., Perosa F., et al. MHC Class I Antigen Processing and Presenting Machinery: Organization, Function, and Defects in Tumor Cells. J. Natl. Cancer Inst. 2013, 105, 1172-1187.
18. Al-Shibli K. I., Donnem T., Al-Saad S., et al. Prognostic Effect of Epithelial and Stromal Lymphocyte Infiltration in Non-Small Cell Lung Cancer. Clin. Cancer Res. 2008, 14, 5220-5227.
19. Fridman W. H., Pages F., Sautes-Fridman C., et al. The Immune Contexture in Human Tumours: Impact on Clinical Outcome. Nat. Rev. Cancer 2012, 12, 298-306.
20. Galon J., Costes A., Sanchez-Cabo F., et al. Type, Density, and Location of Immune Cells within Human Colorectal Tumors Predict Clinical Outcome. Science 2006, 313, 1960-1964.
21. Matsumoto H., Koo S. L., Dent R., et al. Role of Inflammatory Infiltrates in Triple Negative Breast Cancer. J. Clin. Pathol. 2015, 68, 506-510.
22. Nielsen J. S., Sahota R. A., Milne K., et al. CD20+ Tumor-Infiltrating Lymphocytes Have an Atypical CD27- Memory Phenotype and Together with CD8+ T Cells Promote Favorable Prognosis in Ovarian Cancer. Clin. Cancer Res. 2012, 18, 3281-3292.
23. Sato E., Olson S. H., Ahn J., et al. Intraepithelial CD8+ Tumor-Infiltrating Lymphocytes and a High CD8+/Regulatory T Cell Ratio Are Associated with Favorable Prognosis in Ovarian Cancer. Proc. Nat. Acad. Sci. U. S. A. 2005, 102, 18538-18543.
24. Zhang L., Conejo-Garcia J. R., Katsaros D., et al. Intratumoral T Cells, Recurrence, and Survival in Epithelial Ovarian Cancer. N. Engl. J. Med. 2003, 348, 203-213.
25. Bianchini G., Gianni L., The Immune System and Response to HER2-Targeted Treatment in Breast Cancer. Lancet Oncol. 2014, 15, e58-e68.
26. Denkert C., Loibl S., Noske A., et al. Tumor-Associated Lymphocytes as an Independent Predictor of Response to Neoadjuvant Chemotherapy in Breast Cancer. J. Clin. Oncol. 2010, 28, 105-113.
27. Garcia-Martinez E., Gil G. L., Benito A. C., et al. Tumor-Infiltrating Immune Cell Profiles and Their Change after Neoadjuvant Chemotherapy Predict Response and Prognosis of Breast Cancer. Breast Cancer Res. 2014, 16, 488.
28. Galluzzi L., Senovilla L., Vacchelli E., et al. Trial Watch: Dendritic Cell-Based Interventions for Cancer Therapy. Oncoimmunology 2012, 1, 1111-1134.
29. Palucka K., Banchereau J., Dendritic-Cell-Based Therapeutic Cancer Vaccines. Immunity 2013, 39, 38-48.
30. Senovilla L., Vacchelli E., Garcia P., et al. Trial Watch: DNA Vaccines for Cancer Therapy. Oncoimmunology 2013, 2, e23803.
31. Vacchelli E., Martins I., Eggermont A., et al. Trial Watch: Peptide Vaccines in Cancer Therapy. Oncoimmunology 2012, 1, 1557-1576.
32. Kantoff P. W., Higano C. S., Shore N. D., et al. Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer. N. Engl. J. Med. 2010, 363, 411-422.
33. Topalian S. L., Drake C. G., Pardoll D. M., Immune Checkpoint Blockade: A Common Denominator Approach to Cancer Therapy. Cancer Cell 2015, 27, 450-461.
34. Aleksic M., Liddy N., Molloy P. E., et al. Different Affinity Windows for Virus and Cancer-Specific T-Cell Receptors: Implications for Therapeutic Strategies. Eur. J. Immunol. 2012, 42, 3174-3179.
35. Bridgeman J. S., Sewell A. K., Miles J. J., et al. Structural and Biophysical Determinants of Alphabeta T-Cell Antigen Recognition. Immunology 2011, 135, 9-18.
36. Cole D. K., Pumphrey N. J., Boulter J. M., et al. Human TCR-Binding Affinity Is Governed by MHC Class Restriction. J. Immunol. 2007, 178, 5727-5734.
37. Disis M. L., Immune Regulation of Cancer. J. Clin. Oncol. 2010, 28, 4531-4538.
38. Joyce J. A., Fearon D. T., T Cell Exclusion, Immune Privilege, and the Tumor Microenvironment. Science 2015, 348, 74-80.
39. Hodi F. S., O'Day S. J., McDermott D. F., et al. Improved Survival with Ipilimumab in Patients with Metastatic Melanoma. N. Engl. J. Med. 2010, 363, 711-723.
40. Wolchok J. D., Neyns B., Linette G., et al. Ipilimumab Monotherapy in Patients with Pretreated Advanced Melanoma: A Randomised, Double-Blind, Multicentre, Phase 2, Dose-Ranging Study. Lancet Oncol. 2010, 11, 155-164.
41. Topalian S. L., Hodi F. S., Brahmer J. R., et al. Safety, Activity, and Immune Correlates of Anti-PD-1 Antibody in Cancer. N. Engl. J. Med. 2012, 366, 2443-2454.
42. Ribas A., Puzanov I., Dummer R., et al. Pembrolizumab versus Investigator-Choice Chemotherapy for Ipilimumab-Refractory Melanoma (KEYNOTE-002): A Randomised, Controlled, Phase 2 Trial. Lancet Oncol. 2015, 16, 908-918.
43. Garon E. B., Rizvi N. A., Hui R., et al. Pembrolizumab for the Treatment of Non-Small-Cell Lung Cancer. N. Engl. J. Med. 2015, 372, 2018-2028.
44. Brahmer J. R., Tykodi S. S., Chow L. Q., et al. Safety and Activity of Anti-PD-L1 Antibody in Patients with Advanced Cancer. N. Engl. J. Med. 2012, 366, 2455-2465.
45. Weber J. S., Kahler K. C., Hauschild A., Management of Immune-Related Adverse Events and Kinetics of Response with Ipilimumab. J. Clin. Oncol. 2012, 30, 2691-2697.
46. Besser M. J., Shapira-Frommer R., Treves A. J., et al. Clinical Responses in a Phase II Study Using Adoptive Transfer of Short-Term Cultured Tumor Infiltration Lymphocytes in Metastatic Melanoma Patients. Clin. Cancer Res. 2010, 16, 2646-2655.
47. Dudley M. E., Gross C. A., Langhan M. M., et al. CD8+ Enriched "Young" Tumor Infiltrating Lymphocytes Can Mediate Regression of Metastatic Melanoma. Clin. Cancer Res. 2010, 16, 6122-6131.
48. Dudley M. E., Gross C. A., Somerville R. P., et al. Randomized Selection Design Trial Evaluating CD8+-Enriched versus Unselected Tumor-Infiltrating Lymphocytes for Adoptive Cell Therapy for Patients with Melanoma. J. Clin. Oncol. 2013, 31, 2152-2159.
49. Dudley M. E., Wunderlich J. R., Yang J. C., et al. Adoptive Cell Transfer Therapy following Non-Myeloablative but Lymphodepleting Chemotherapy for the Treatment of Patients with Refractory Metastatic Melanoma. J. Clin. Oncol. 2005, 23, 2346-2357.
50. Rosenberg S. A., Yang J. C., Sherry R. M., et al. Durable Complete Responses in Heavily Pretreated Patients with Metastatic Melanoma Using T-Cell Transfer Immunotherapy. Clin. Cancer Res. 2011, 17, 4550-4557.
51. Lu Y. C., Yao X., Crystal J. S., et al. Efficient Identification of Mutated Cancer Antigens Recognized by T Cells Associated with Durable Tumor Regressions. Clin. Cancer Res. 2014, 20, 3401-3410.
52. Schumacher T. N., Schreiber R. D., Neoantigens in Cancer Immunotherapy. Science 2015, 348, 69-74.
53. Greenman C., Stephens P., Smith R., et al. Patterns of Somatic Mutation in Human Cancer Genomes. Nature 2007, 446, 153-158.
54. Mar V. J., Wong S. Q., Li J., et al. BRAF/NRAS Wild-Type Melanomas Have a High Mutation Load Correlating with Histologic and Molecular Signatures of UV Damage. Clin. Cancer Res. 2013, 19, 4589-4598.
55. Barrett D. M., Singh N., Porter D. L., et al. Chimeric Antigen Receptor Therapy for Cancer. Annu. Rev. Med. 2014, 65, 333-347.
56. Bargou R., Leo E., Zugmaier G., et al. Tumor Regression in Cancer Patients by Very Low Doses of a T Cell-Engaging Antibody. Science 2008, 321, 974-977.
57. Frankel S. R., Baeuerle P. A., Targeting T Cells to Tumor Cells Using Bispecific Antibodies. Curr. Opin. Chem. Biol. 2013, 17, 385-392.
58. Seimetz D., Novel Monoclonal Antibodies for Cancer Treatment: The Trifunctional Antibody Catumaxomab (Removab). J. Cancer 2011, 2, 309-316.
59. Cohen M., Reiter Y., T-Cell Receptor-Like Antibodies: Targeting the Intracellular Proteome Therapeutic Potential and Clinical Applications. Antibodies 2013, 2, 517-534.
60. Dahan R., Reiter Y., T-Cell-Receptor-Like Antibodies-Generation, Function and Applications. Exp. Rev. Mol. Med. 2012, 14, e6.
61. Bossi G., Gerry A. B., Paston S. J., et al. Examining the Presentation of Tumor Associated Antigens on Peptide-Pulsed T2 Cells. Oncoimmunology 2013, 2, e26840.
62. Liddy N., Bossi G., Adams K. J., et al. Monoclonal TCR-Redirected Tumor Cell Killing. Nat. Med. 2012, 18, 980-987.
63. McCormack E., Adams K. J., Hassan N. J., et al. Bi-Specific TCR-Anti CD3 Redirected T-Cell Targeting of NY-ESO-1- and LAGE-1-Positive Tumors. Cancer Immunol. Immunother. 2013, 62, 773-785.
64. Oates J., Jakobsen B. K., ImmTACs: Novel Bi-Specific Agents for Targeted Cancer Therapy. Oncoimmunology 2013, 2, e22891.
65. Pierce B. G., Hellman L. M., Hossain M., et al. Computational Design of the Affinity and Specificity of a Therapeutic T Cell Receptor. PLoS Comput. Biol. 2014, 10, e1003478.
66. Smith S. N., Harris D. T., Kranz D. M., T Cell Receptor Engineering and Analysis Using the Yeast Display Platform. Methods Mol. Biol. 2015, 1319, 95-141.
67. Dunn S. M., Rizkallah P. J., Baston E., et al. Directed Evolution of Human T Cell Receptor CDR2 Residues by Phage Display Dramatically Enhances Affinity for Cognate Peptide-MHC without Increasing Apparent Cross-Reactivity. Protein Sci. 2006, 15, 710-721.
68. Li Y., Moysey R., Molloy P. E., et al. Directed Evolution of Human T-Cell Receptors with Picomolar Affinities by Phage Display. Nat. Biotechnol. 2005, 23, 349-354.
69. Boulter J. M., Glick M., Todorov P. T., et al. Stable, Soluble T-Cell Receptor Molecules for Crystallization and Therapeutics. Protein Eng. 2003, 16, 707-711.
70. Purbhoo M. A., Li Y., Sutton D. H., et al. The HLA A∗0201-Restricted hTERT(540-548) Peptide Is Not Detected on Tumor Cells by a CTL Clone or a High-Affinity T-Cell Receptor. Mol. Cancer Ther. 2007, 6, 2081-2091.
71. Purbhoo M. A., Sutton D. H., Brewer J. E., et al. Quantifying and Imaging NY-ESO-1/LAGE-1-Derived Epitopes on Tumor Cells Using High Affinity T Cell Receptors. J. Immunol. 2006, 176, 7308-7316.
72. Sami M., Rizkallah P. J., Dunn S., et al. Crystal Structures of High Affinity Human T-Cell Receptors Bound to Peptide Major Histocompatibility Complex Reveal Native Diagonal Binding Geometry. Protein Eng. Des. Sel. 2007, 20, 397-403.
73. Moser J. C., Pulido J. S., Dronca R. S., et al. The Mayo Clinic Experience with the Use of Kinase Inhibitors, Ipilimumab, Bevacizumab, and Local Therapies in the Treatment of Metastatic Uveal Melanoma. Melanoma Res. 2015, 25, 59-63.
74. Johnson L. A., Morgan R. A., Dudley M. E., et al. Gene Therapy with Human and Mouse T-Cell Receptors Mediates Cancer Regression and Targets Normal Tissues Expressing Cognate Antigen. Blood 2009, 114, 535-546.
75. Morgan R. A., Chinnasamy N., Abate-Daga D., et al. Cancer Regression and Neurological Toxicity following Anti-MAGE-A3 TCR Gene Therapy. J. Immunother. 2013, 36, 133-351.
76. Robbins P. F., Morgan R. A., Feldman S. A., et al. Tumor Regression in Patients with Metastatic Synovial Cell Sarcoma and Melanoma Using Genetically Engineered Lymphocytes Reactive with NY-ESO-1. J. Clin. Oncol. 2011, 29, 917-924.
77. Rapoport A. P., Stadtmauer E. A., Binder-Scholl G. K., et al. NY-ESO-1-Specific TCR-Engineered T Cells Mediate Sustained Antigen-Specific Antitumor Effects in Myeloma. Nat. Med. 2015, 21, 914-921.
78. Zhao Y., Bennett A. D., Zheng Z., et al. High-Affinity TCRs Generated by Phage Display Provide CD4+ T Cells with the Ability to Recognize and Kill Tumor Cell Lines. J. Immunol. 2007, 179, 5845-5854.
79. Stone J. D., Chervin A. S., Kranz D. M., T-Cell Receptor Binding Affinities and Kinetics: Impact on T-Cell Activity and Specificity. Immunology 2009, 126, 165-176.
80. Stone J. D., Kranz D. M., Role of T Cell Receptor Affinity in the Efficacy and Specificity of Adoptive T Cell Therapies. Front. Immunol. 2013, 4, 244.
81. Feltkamp M. C., Smits H. L., Vierboom M. P., et al. Vaccination with Cytotoxic T Lymphocyte Epitope-Containing Peptide Protects against a Tumor Induced by Human Papillomavirus Type 16-Transformed Cells. Eur. J. Immunol. 1993, 23, 2242-2249.
82. Stauss H. J., Davies H., Sadovnikova E., et al. Induction of Cytotoxic T Lymphocytes with Peptides In Vitro: Identification of Candidate T-Cell Epitopes in Human Papilloma Virus. Proc. Nat. Acad. Sci. U. S. A. 1992, 89, 7871-7875.
83. Chen W., Peace D. J., Rovira D. K., et al. T-Cell Immunity to the Joining Region of p210BCR-ABL Protein. Proc. Nat. Acad. Sci. U. S. A. 1992, 89, 1468-1472.
84. DeLeo A. B., Jay G., Appella E., et al. Detection of a Transformation-Related Antigen in Chemically Induced Sarcomas and Other Transformed Cells of the Mouse. Proc. Nat. Acad. Sci. U. S. A. 1979, 76, 2420-2424.
85. Peace D. J., Chen W., Nelson H., et al. T Cell Recognition of Transforming Proteins Encoded by Mutated Ras Proto-Oncogenes. J. Immunol. 1991, 146, 2059-2065.
86. Peace D. J., Smith J. W., Disis M. L., et al. Induction of T Cells Specific for the Mutated Segment of Oncogenic P21ras Protein by Immunization In Vivo with the Oncogenic Protein. J. Immunother. Emphasis Tumor Immunol. 1993, 14, 110-114.
87. Skipper J., Stauss H. J., Identification of Two Cytotoxic T Lymphocyte-Recognized Epitopes in the Ras Protein. J. Exp. Med. 1993, 177, 1493-1498.
88. Alexandrov L. B., Nik-Zainal S., Wedge D. C., et al. Signatures of Mutational Processes in Human Cancer. Nature 2013, 500, 415-421.
89. Caballero O. L., Chen Y. T., Cancer/Testis (CT) Antigens: Potential Targets for Immunotherapy. Cancer Sci. 2009, 100, 2014-2021.
90. Chen Y. T., Gure A. O., Tsang S., et al. Identification of Multiple Cancer/Testis Antigens by Allogeneic Antibody Screening of a Melanoma Cell Line Library. Proc. Nat. Acad. Sci. U. S. A. 1998, 95, 6919-6923.
91. Fukuyama T., Hanagiri T., Takenoyama M., et al. Identification of a New Cancer/Germline Gene, KK-LC-1, Encoding an Antigen Recognized by Autologous CTL Induced on Human Lung Adenocarcinoma. Cancer Res. 2006, 66, 4922-4928.
92. Lee S.-Y., Williamson B., Caballero O. L., et al. Identification of the Gonad-Specific Anion Transporter SLCO6A1 as a Cancer/Testis (CT) Antigen Expressed in Human Lung Cancer. Cancer Immun. 2004, 4, 13.
93. Liggins A. P., Brown P. J., Asker K., et al. A Novel Diffuse Large B-Cell Lymphoma-Associated Cancer Testis Antigen Encoding a PAS Domain Protein. Br. J. Cancer 2004, 91, 141-149.
94. Sahin U., Tureci O., Schmitt H., et al. Human Neoplasms Elicit Multiple Specific Immune Responses in the Autologous Host. Proc. Nat. Acad. Sci. U. S. A. 1995, 92, 11810-11813.
95. Chen Y. T., Scanlan M. J., Sahin U., et al. A Testicular Antigen Aberrantly Expressed in Human Cancers Detected by Autologous Antibody Screening. Proc. Nat. Acad. Sci. U. S. A. 1997, 94, 1914-1918.
96. Lee S. Y., Obata Y., Yoshida M., et al. Immunomic Analysis of Human Sarcoma. Proc. Nat. Acad. Sci. U. S. A. 2003, 100, 2651-2656.
97. Ono T., Kurashige T., Harada N., et al. Identification of Proacrosin Binding Protein sp32 Precursor as a Human Cancer/Testis Antigen. Proc. Nat. Acad. Sci. U. S. A. 2001, 98, 3282-3287.
98. Park S., Lim Y., Lee D., et al. Identification and Characterization of a Novel Cancer/Testis Antigen Gene CAGE-1. Biochim. Biophys. Acta 2003, 1625, 173-182.
99. Türeci Ö., Sahin U., Schobert I., et al. The SSX-2 Gene, Which Is Involved in the t (X; 18) Translocation of Synovial Sarcomas, Codes for the Human Tumor Antigen HOM-MEL-40. Cancer Res. 1996, 56, 4766-4772.
100. Türeci Ö., Sahin U., Zwick C., et al. Identification of a Meiosis-Specific Protein as a Member of the Class of Cancer/Testis Antigens. Proc. Nat. Acad. Sci. U. S. A. 1998, 95, 5211-5216.
101. Fiszer D., Kurpisz M., Major Histocompatibility Complex Expression on Human, Male Germ Cells: A Review. Am. J. Reprod. Immunol. 1998, 40, 172-176.
102. Feichtinger J., Aldeailej I., Anderson R., et al. Meta-Analysis of Clinical Data Using Human Meiotic Genes Identifies a Novel Cohort Of Highly Restricted Cancer-Specific Marker Genes. Oncotarget 2012, 3, 843-853.
103. Epping M. T., Wang L., Edel M. J., et al. The Human Tumor Antigen PRAME Is a Dominant Repressor of Retinoic Acid Receptor Signaling. Cell 2005, 122, 835-847.
104. Monte M., Simonatto M., Peche L. Y., et al. MAGE-A Tumor Antigens Target p53 Transactivation Function through Histone Deacetylase Recruitment and Confer Resistance to Chemotherapeutic Agents. Proc. Nat. Acad. Sci. U. S. A. 2006, 103, 11160-11165.
105. Yang B., O'Herrin S. M., Wu J., et al. MAGE-A, mMage-b, and MAGE-C Proteins form Complexes with KAP1 and Suppress p53-Dependent Apoptosis in MAGE-Positive Cell Lines. Cancer Res. 2007, 67, 9954-9962.
106. Feichtinger J., Larcombe L., McFarlane R. J., Meta-Analysis of Expression of l (3) mbt Tumor-Associated Germline Genes Supports the Model That a Soma-to-Germline Transition Is a Hallmark of Human Cancers. Int. J. Cancer 2014, 134, 2359-2365.
107. Janic A., Mendizabal L., Llamazares S., et al. Ectopic Expression of Germline Genes Drives Malignant Brain Tumor Growth in Drosophila. Science 2010, 330, 1824-1827.
108. Liyanage U. K., Moore T. T., Joo H.-G., et al. Prevalence of Regulatory T Cells Is Increased in Peripheral Blood and Tumor Microenvironment of Patients with Pancreas or Breast Adenocarcinoma. J. Immunol. 2002, 169, 2756-2761.
109. Wang J., Emadali A., Le Bescont A., et al. Induced Malignant Genome Reprogramming in Somatic Cells by Testis-Specific Factors. Biochim. Biophys. Acta 2011, 1809, 221-225.
110. Wang J., Rousseaux S., Khochbin S., Sustaining Cancer through Addictive Ectopic Gene Activation. Curr. Opin. Oncol. 2014, 26, 73-77.
111. De Smet C., De Backer O., Faraoni I., et al. The Activation of Human Gene MAGE-1 in Tumor Cells Is Correlated with Genome-Wide Demethylation. Proc. Nat. Acad. Sci. U. S. A. 1996, 93, 7149-7153.
112. Grunau C., Sanchez C., Ehrlich M., et al. Frequent DNA Hypomethylation of Human Juxtacentromeric BAGE Loci in Cancer. Genes Chromosomes Cancer 2005, 43, 11-24.
113. Weber J., Salgaller M., Samid D., et al. Expression of the MAGE-1 Tumor Antigen Is Up-Regulated by the Demethylating Agent 5-Aza-2′-Deoxycytidine. Cancer Res. 1994, 54, 1766-1771.
114. Old L. J., Cancer/Testis (CT) Antigens-A New Link between Gametogenesis and Cancer. Cancer Immun. 2001, 1, 1.
115. Simpson A. J., Caballero O. L., Jungbluth A., et al. Cancer/Testis Antigens, Gametogenesis and Cancer. Nat. Rev. Cancer 2005, 5, 615-625.
116. Almeida L. G., Sakabe N. J., deOliveira A. R., et al. CTdatabase: A Knowledge-Base of High-Throughput and Curated Data on Cancer-Testis Antigens. Nucleic Acids Res. 2009, 37, D816-D819.
117. Hofmann O., Caballero O. L., Stevenson B. J., et al. Genome-Wide Analysis of Cancer/Testis Gene Expression. Proc. Nat. Acad. Sci. U. S. A. 2008, 105, 20422-20427.
118. Gotter J., Brors B., Hergenhahn M., et al. Medullary Epithelial Cells of the Human Thymus Express a Highly Diverse Selection of Tissue-Specific Genes Colocalized in Chromosomal Clusters. J. Exp. Med. 2004, 199, 155-166.
119. Whitehurst A. W., Cause and Consequence of Cancer/Testis Antigen Activation in Cancer. Annu. Rev. Pharmacol. Toxicol. 2014, 54, 251-272.
120. Chen Y. T., Hsu M., Lee P., et al. Cancer/Testis Antigen CT45: Analysis of mRNA and Protein Expression in Human Cancer. Int. J. Cancer. 2009, 124, 2893-2898.
121. Grigoriadis A., Caballero O. L., Hoek K. S., et al. CT-X Antigen Expression in Human Breast Cancer. Proc. Nat. Acad. Sci. U. S. A. 2009, 106, 13493-13498.
122. Jungbluth A. A., Stockert E., Chen Y. T., et al. Monoclonal Antibody MA454 Reveals a Heterogeneous Expression Pattern of MAGE-1 Antigen in Formalin-Fixed Paraffin Embedded Lung Tumours. Br. J. Cancer 2000, 83, 493-497.
123. Sigalotti L., Fratta E., Coral S., et al. Intratumor Heterogeneity of Cancer/Testis Antigens Expression in Human Cutaneous Melanoma Is Methylation-Regulated and Functionally Reverted by 5-Aza-2′-Deoxycytidine. Cancer Res. 2004, 64, 9167-9171.
124. Barker A. B., Schreurs M. W., Tafazzul G., et al. Identification of a Novel Peptide Derived from the Melanocyte-Specific gp100 Antigen as the Dominant Epitope Recognized by an HLA-A2. 1-Restricted Anti-Melanoma CTL Line. Int. J. Cancer 1995, 62, 97-102.
125. Brichard V., Van Pel A., Wolfel T., et al. The Tyrosinase Gene Codes for an Antigen Recognized by Autologous Cytolytic T Lymphocytes on HLA-A2 Melanomas. J. Exp. Med. 1993, 178, 489-495.
126. Coulie P. G., Brichard V., Van Pel A., et al. A New Gene Coding for a Differentiation Antigen Recognized by Autologous Cytolytic T Lymphocytes on HLA-A2 Melanomas. J. Exp. Med. 1994, 180, 35-42.
127. Cox A. L., Skipper J., Chen Y., et al. Identification of a Peptide Recognized by Five Melanoma-Specific Human Cytotoxic T Cell Lines. Science 1994, 264, 716-719.
128. Kawakami Y., Eliyahu S., Delgado C. H., et al. Cloning of the Gene Coding for a Shared Human Melanoma Antigen Recognized by Autologous T Cells Infiltrating into Tumor. Proc. Nat. Acad. Sci. U. S. A. 1994, 91, 3515-3519.
129. Kawakami Y., Eliyahu S., Delgado C. H., et al. Identification of a Human Melanoma Antigen Recognized by Tumor-Infiltrating Lymphocytes Associated with In Vivo Tumor Rejection. Proc. Nat. Acad. Sci. U. S. A. 1994, 91, 6458-6462.
130. Kawakami Y., Eliyahu S., Sakaguchi K., et al. Identification of the Immunodominant Peptides of the MART-1 Human Melanoma Antigen Recognized by the Majority of HLA-A2-Restricted Tumor Infiltrating Lymphocytes. J. Exp. Med. 1994, 180, 347-352.
131. Wolfel T., Van Pel A., Brichard V., et al. Two Tyrosinase Nonapeptides Recognized on HLA-A2 Melanomas by Autologous Cytolytic T Lymphocytes. Eur. J. Immunol. 1994, 24, 759-764.
132. Coulie P. G., Van den Eynde B. J., van der Bruggen P., et al. Tumour Antigens Recognized by T Lymphocytes: At the Core of Cancer Immunotherapy. Nat. Rev. Cancer 2014, 14, 135-146.
133. Van Driessche A., Berneman Z. N., Van Tendeloo V. F., Active Specific Immunotherapy Targeting the Wilms' Tumor Protein 1 (WT1) for Patients with Hematological Malignancies and Solid Tumors: Lessons from Early Clinical Trials. Oncologist 2012, 17, 250-259.
134. Katsha A., Belkhiri A., Goff L., et al. Aurora Kinase A in Gastrointestinal Cancers: Time to Target. Mol. Cancer 2015, 14, 106.
135. Kumar S., Kim J., PLK-1 Targeted Inhibitors and Their Potential against Tumorigenesis. BioMed Res. Int. 2015, 2015, 705745.
136. Tamura K., Development of Cell-Cycle Checkpoint Therapy for Solid Tumors. Jpn. J. Clin. Oncol. 2015, 45, 1097-1102.
137. Ledoux A. C., Perkins N. D., NF-kappaB and the Cell Cycle. Biochem. Soc. Trans. 2014, 42, 76-81.
138. Cobbold M., De La Pena H., Norris A., et al. MHC Class I-Associated Phosphopeptides Are the Targets of Memory-Like Immunity in Leukemia. Sci. Trans. Med. 2013, 5, 203ra125.
139. Dalet A., Robbins P. F., Stroobant V., et al. An Antigenic Peptide Produced by Reverse Splicing and Double Asparagine Deamidation. Proc. Nat. Acad. Sci. U. S. A. 2011, 108, E323-E331.
140. Skipper J. C., Hendrickson R. C., Gulden P. H., et al. An HLA-A2-restricted Tyrosinase Antigen on Melanoma Cells Results from Posttranslational Modification and Suggests a Novel Pathway for Processing of Membrane Proteins. J. Exp. Med. 1996, 183, 527-534.
141. Zarling A. L., Obeng R. C., Desch A. N., et al. MHC-Restricted Phosphopeptides from Insulin Receptor Substrate-2 and CDC25b Offer Broad-Based Immuno-therapeutic Agents for Cancer. Cancer Res. 2014, 74, 6784-6795.
142. Zarling A. L., Polefrone J. M., Evans A. M., et al. Identification of Class I MHC-Associated Phosphopeptides as Targets for Cancer Immunotherapy. Proc. Nat. Acad. Sci. U. S. A. 2006, 103, 14889-14894.
143. Cheever M. A., Allison J. P., Ferris A. S., et al. The Prioritization of Cancer Antigens: A National Cancer Institute Pilot Project for the Acceleration of Translational Research. Clin. Cancer Res. 2009, 15, 5323-5337.
144. Morgan R. A., Yang J. C., Kitano M., et al. Case Report of a Serious Adverse Event following the Administration of T Cells Transduced with a Chimeric Antigen Receptor Recognizing ERBB2. Mol. Ther. 2010, 18, 843-851.
145. Parkhurst M. R., Yang J. C., Langan R. C., et al. T Cells Targeting Carcinoembryonic Antigen Can Mediate Regression of Metastatic Colorectal Cancer but Induce Severe Transient Colitis. Mol. Ther. 2011, 19, 620-626.
146. Sammut S. J., Feichtinger J., Stuart N., et al. A Novel Cohort of Cancer-Testis Biomarker Genes Revealed through Meta-Analysis of Clinical Data Sets. Oncoscience 2014, 1, 349-359.
147. Berlin C., Kowalewski D. J., Schuster H., et al. Mapping the HLA Ligandome Landscape of Acute Myeloid Leukemia: A Targeted Approach toward Peptide-Based Immunotherapy. Leukemia 2015, 29, 647-659.
148. Rammensee H. G., Singh-Jasuja H., HLA Ligandome Tumor Antigen Discovery for Personalized Vaccine Approach. Expert Rev. Vaccines 2013, 12, 1211-1217.
149. Rammensee H., Bachmann J., Emmerich N. P., et al. SYFPEITHI: Database for MHC Ligands and Peptide Motifs. Immunogenetics 1999, 50, 213-219.
150. Parker K. C., Bednarek M. A., Coligan J. E., Scheme for Ranking Potential HLA-A2 Binding Peptides Based on Independent Binding of Individual Peptide Side-Chains. J. Immunol. 1994, 152, 163-175.
151. Fritsch E. F., Rajasagi M., Ott P. A., et al. HLA-Binding Properties of Tumor Neoepitopes in Humans. Cancer Immunol. Res. 2014, 2, 522-529.
152. Hakenberg J., Nussbaum A. K., Schild H., et al. MAPPP: MHC Class I Antigenic Peptide Processing Prediction. Appl. Bioinformatics 2003, 2, 155-158.
153. McCarthy M. K., Weinberg J. B., The Immunoproteasome and Viral Infection: A Complex Regulator of Inflammation. Front. Microbiol. 2015, 6, 21.
154. Gras S., Burrows S. R., Turner S. J., et al. A Structural Voyage toward an Understanding of the MHC-I-Restricted Immune Response: Lessons Learned and Much to Be Learned. Immunol. Rev. 2012, 250, 61-81.
155. Takeshita L. Y., Jones A. R., Gonzalez-Galarza F. F., et al. Allele Frequencies Database. Transfus. Med. Hemother. 2014, 41, 352-355.
156. Platzer B., Stout M., Fiebiger E., Antigen Cross-Presentation of Immune Complexes. Front. Immunol. 2014, 5, 140.
157. Berard F., Blanco P., Davoust J., et al. Cross-Priming of Naive CD8 T Cells against Melanoma Antigens Using Dendritic Cells Loaded with Killed Allogeneic Melanoma Cells. J. Exp. Med. 2000, 192, 1535-1544.
158. Goc J., Fridman W. H., Sautes-Fridman C., et al. Characteristics of Tertiary Lymphoid Structures in Primary Cancers. Oncoimmunology 2013, 2, e26836.
159. Spiotto M. T., Rowley D. A., Schreiber H., Bystander Elimination of Antigen Loss Variants in Established Tumors. Nat. Med. 2004, 10, 294-298.
160. Wolkers M. C., Brouwenstijn N., Bakker A. H., et al. Antigen Bias in T Cell Cross-Priming. Science 2004, 304, 1314-1317.
161. Bossi G., Buisson S., Oates J., et al. ImmTAC-Redirected Tumour Cell Killing Induces and Potentiates Antigen Cross-Presentation by Dendritic Cells. Cancer Immunol. Immunother. 2014, 63, 437-448.
162. Scholler J., Brady T. L., Binder-Scholl G., et al. Decade-Long Safety and Function of Retroviral-Modified Chimeric Antigen Receptor T Cells. Science Trans. Med. 2012, 4, 132ra53.
163. Linette G. P., Stadtmauer E. A., Maus M. V., et al. Cardiovascular Toxicity and Titin Cross-Reactivity of Affinity-Enhanced T Cells in Myeloma and Melanoma. Blood 2013, 122, 863-871.
164. Cameron B. J., Gerry A. B., Dukes J., et al. Identification of a Titin-Derived HLA-A1-Presented Peptide as a Cross-Reactive Target for Engineered MAGE A3-Directed T Cells. Science Trans. Med. 2013, 5, 197ra103.
165. Oates J., Hassan N. J., Jakobsen B. K., ImmTacs for Targeted Cancer Therapy: Why, What, How, and Which. Mol. Immunol. 2015, 67, 67-74.
166. Ajani J. A., Song S., Hochster H. S., et al. Cancer Stem Cells: The Promise and the Potential. Semin. Oncol. 2015, 42, S3-17.
167. Ramskold D., Luo S., Wang Y. C., et al. Full-Length mRNA-Seq from Single-Cell Levels of RNA and Individual Circulating Tumor Cells. Nat. Biotech. 2012, 30, 777-782.
168. Powell A. A., Talasaz A. H., Zhang H., et al. Single Cell Profiling of Circulating Tumor Cells: Transcriptional Heterogeneity and Diversity from Breast Cancer Cell Lines. PLoS One 2012, 7, e33788.
169. Dudley M. E., Wunderlich J. R., Robbins P. F., et al. Cancer Regression and Autoimmunity in Patients after Clonal Repopulation with Antitumor Lymphocytes. Science 2002, 298, 850-854.
170. Morgan R. A., Dudley M. E., Wunderlich J. R., et al. Cancer Regression in Patients after Transfer of Genetically Engineered Lymphocytes. Science 2006, 314, 126-129.
171. Grupp S. A., Kalos M., Barrett D., et al. Chimeric Antigen Receptor-Modified T Cells for Acute Lymphoid Leukemia. N. Engl. J. Med. 2013, 368, 1509-1518.
172. Kalos M., Levine B. L., Porter D. L., et al. T Cells with Chimeric Antigen Receptors Have Potent Antitumor Effects and Can Establish Memory in Patients with Advanced Leukemia. Sci. Trans. Med. 2011, 3, 95ra73-95ra73.
173. Robbins P. F., Dudley M. E., Wunderlich J., et al. Cutting Edge: Persistence of Transferred Lymphocyte Clonotypes Correlates with Cancer Regression in Patients Receiving Cell Transfer Therapy. J. Immunol. 2004, 173, 7125-7130.
174. Hinrichs C. S., Borman Z. A., Gattinoni L., et al. Human Effector CD8+ T Cells Derived from Naive Rather Than Memory Subsets Possess Superior Traits for Adoptive Immunotherapy. Blood 2011, 117, 808-814.
175. Powell D. J. Jr., Dudley M. E., Robbins P. F., et al. Transition of Late-Stage Effector T Cells to CD27+ CD28+ Tumor-Reactive Effector Memory T Cells in Humans after Adoptive Cell Transfer Therapy. Blood 2005, 105, 241-250.
176. Tran K. Q., Zhou J., Durflinger K. H., et al. Minimally Cultured Tumor-Infiltrating Lymphocytes Display Optimal Characteristics for Adoptive Cell Therapy. J. Immunother. 2008, 31, 742-751.
177. Melenhorst J. J., Scheinberg P., Chattopadhyay P. K., et al. High Avidity Myeloid Leukemia-Associated Antigen-Specific CD8+ T Cells Preferentially Reside in the Bone Marrow. Blood 2009, 113, 2238-2244.
178. Boutros P. C., Fraser M., Harding N. J., et al. Spatial Genomic Heterogeneity within Localized, Multifocal Prostate Cancer. Nat. Genet. 2015, 47, 736-745.
179. Greaves M., Maley C. C., Clonal Evolution in Cancer. Nature 2012, 481, 306-313.